Works by Ahn, Jin Hee

Results: 176
    1

    Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.

    Published in:
    2015
    By:
    • Yoon Ji Choi;
    • Dae Ho Lee;
    • Chang Min Choi;
    • Jung Shin Lee;
    • Seung Jin Lee;
    • Jin-Hee Ahn;
    • Sang-We Kim;
    • Choi, Yoon Ji;
    • Lee, Dae Ho;
    • Choi, Chang Min;
    • Lee, Jung Shin;
    • Lee, Seung Jin;
    • Ahn, Jin-Hee;
    • Kim, Sang-We
    Publication type:
    journal article
    2
    3

    Visualization and Isolation of Langerhans Islets by a Fluorescent Probe PiY.

    Published in:
    Angewandte Chemie, 2013, v. 125, n. 33, p. 8719, doi. 10.1002/ange.201302149
    By:
    • Kang, Nam ‐ Young;
    • Lee, Sung ‐ Chan;
    • Park, Sung ‐ Jin;
    • Ha, Hyung ‐ Ho;
    • Yun, Seong ‐ Wook;
    • Kostromina, Elena;
    • Gustavsson, Natalia;
    • Ali, Yusuf;
    • Chandran, Yogeswari;
    • Chun, Hang ‐ Suk;
    • Bae, MyungAe;
    • Ahn, Jin Hee;
    • Han, Weiping;
    • Radda, George K.;
    • Chang, Young ‐ Tae
    Publication type:
    Article
    4
    5
    6
    7
    8

    ENOblock inhibits the pathology of diet-induced obesity.

    Published in:
    Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-36715-3
    By:
    • Cho, Haaglim;
    • Lee, Ji-Hyung;
    • Um, JungIn;
    • Kim, Sunwook;
    • Kim, Yukyung;
    • Kim, Woong-Hee;
    • Kim, Yong Sook;
    • Pagire, Haushabhau S.;
    • Ahn, Jin Hee;
    • Ahn, Youngkeun;
    • Chang, Young-Tae;
    • Jung, Da-Woon;
    • Williams, Darren R.
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Association between tumor <sup>18</sup>F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-11603-z
    By:
    • Chae, Sun Young;
    • Park, Seol Hoon;
    • Lee, Hyo Sang;
    • Ahn, Jin-Hee;
    • Kim, Sung-Bae;
    • Jung, Kyung Hae;
    • Kim, Jeong Eun;
    • Ahn, Sei Hyun;
    • Son, Byung Ho;
    • Lee, Jong Won;
    • Ko, Beom Seok;
    • Kim, Hee Jeong;
    • Gong, Gyungyub;
    • Oh, Jungsu S.;
    • Park, Seo Young;
    • Moon, Dae Hyuk
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Predictive and prognostic value of <sup>18</sup>F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2025, v. 52, n. 6, p. 2096, doi. 10.1007/s00259-024-07058-1
    By:
    • Jeong, Hyehyun;
    • Ryu, Jeongryul;
    • Jeong, Jae Ho;
    • Han, Sangwon;
    • Hyung, Jaewon;
    • Ahn, Jin-Hee;
    • Jung, Kyung Hae;
    • Kim, Sung-Bae;
    • Jeong, Byung-Kwan;
    • Lee, Hee Jin;
    • Gong, Gyungyub;
    • Moon, Dae Hyuk
    Publication type:
    Article
    36

    Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.

    Published in:
    2016
    By:
    • Park, Ji;
    • Kang, Myung;
    • Ahn, Jin-Hee;
    • Kim, Jeong;
    • Jung, Kyung;
    • Gong, Gyungyub;
    • Lee, Hee;
    • Son, Byung-Ho;
    • Ahn, Sei-Hyun;
    • Kim, Hak-Hee;
    • Shin, Hee;
    • Moon, Dae-Hyuk;
    • Kim, Sung-Bae;
    • Park, Ji Hyun;
    • Kang, Myung Joo;
    • Kim, Jeong Eun;
    • Jung, Kyung Hae;
    • Lee, Hee Jin;
    • Shin, Hee Jung
    Publication type:
    journal article
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial.

    Published in:
    International Journal of Cancer, 2018, v. 143, n. 12, p. 3240, doi. 10.1002/ijc.31651
    By:
    • Park, Yeon Hee;
    • Lee, Kyung‐Hun;
    • Sohn, Joo Hyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee‐Hyun;
    • Lee, Ki Hyeong;
    • Ahn, Jin Seok;
    • Kim, Tae‐Yong;
    • Kim, Gun Min;
    • Park, In Hae;
    • Kim, Sung‐Bae;
    • Kim, Se Hyun;
    • Han, Hye Sook;
    • Im, Young‐Hyuck;
    • Ahn, Jin‐Hee;
    • Kim, Jung‐Yong;
    • Kang, Jahoon;
    • Im, Seock‐Ah
    Publication type:
    Article
    47
    48
    49

    Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2019, v. 26, n. 7, p. 2166, doi. 10.1245/s10434-019-07332-9
    By:
    • Gwark, Sung-chan;
    • Lee, Han Shin;
    • Lee, Youngjoo;
    • Lee, Sae Byul;
    • Sohn, Guiyun;
    • Kim, Jisun;
    • Chung, Il Yong;
    • Ko, Beom Seok;
    • Kim, Hee Jeong;
    • Son, Byung Ho;
    • Ahn, Jin-Hee;
    • Jung, Kyung Hae;
    • Kim, Sung-Bae;
    • Lee, Hee Jin;
    • Gong, Gyung-Yub;
    • Ahn, Sei Hyun;
    • Lee, Jong Won
    Publication type:
    Article
    50